FDA Grants Orphan Drug Designation for Fabry Disease Treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for FLT190 for the treatment of Fabry Disease.
“Receiving Orphan Drug Designation from the FDA is another step forward for the development of FLT190 for patients with Fabry Disease,” said Chris Hollowood, Chairman of Freeline in a company press release. “Fabry Disease has a wide spectrum of symptoms that can have a devastating impact on people’s lives and we believe that FLT190 has the potential to be a functional cure that can halt progression of the disease and address many of these serious symptoms.”
Read the full press release here.